Concepedia

Ivica Fucek

IF

Statistics

Publications

11

Citations

669

H-Index

11

Active since

2014

Affiliations

Affimed Therapeutics (Germany)(Current)

Ivica Fucek is an author at Affimed Therapeutics (Germany) specializing in immunology, cancer immunology, and bispecific antibodies.

Publications per year

2014–2022

11

Publications

11

A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30<sup>+</sup>tumor cells

Uwe Reusch, Carmen Burkhardt, Ivica Fucek et al. · mAbs · 2014 · 159 citations · Full text

, , +17

A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19<sup>+</sup>tumor cells

Uwe Reusch, Johannes Duell, Kristina Ellwanger et al. · mAbs · 2015 · 127 citations · Full text

, , +17

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia

Uwe Reusch, Kimberly H. Harrington, Chelsea J. Gudgeon et al. · Clinical Cancer Research · 2016 · 89 citations · Full text

, , +17

Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity

Kristina Ellwanger, Uwe Reusch, Ivica Fucek et al. · mAbs · 2019 · 65 citations · Full text

, , +17

Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors

Susanne Wingert, Uwe Reusch, Stefan Knackmuss et al. · mAbs · 2021 · 65 citations · Full text

, , +17

1–5 of 11